The National Institute of Health and Care Excellence has recommended that surgeons working in hospitals with limited or no access to a radiopharmacy
department could now use Magtrace and Sentimag as an option to locate sentinel lymph nodes in people with breast cancer.
The recommendation in draft NICE medical technology guidance could see a change in NHS standard care for the first time in years. The technology could also mitigate
the reliance on radioactive isotope tracers shipped in from outside Great Britain.
The magnetic liquid tracer - Magtrace - is a non-radioactive dark brown liquid. It is both a magnetic marker and a visual dye. The Magtrace is injected into the
tissue around a tumour. The particles are then absorbed into the lymphatic system, following the route that cancer cells are most likely to take when they spread
from the primary tumour and become trapped in sentinel lymph nodes.
The Sentimag probe moves over the skin emitting sounds of different pitches as it passes over the Magtrace tracer, in a similar way to a metal detector locating
metal in the ground. The nodes often appear dark brown or black in colour, which also helps with identification.
Many are well informed about different diseases that involve oral cavities. Fortunately, several medications assist in treating these diseases. Dentists or
dental professionals prescribe drugs for dental care, depending on the issue. Specific medications are offered to prevent or treat infection, reduce anxiety,
minimize pain and inflammation, treat bacterial infections, teeth cleaning or whitening, and many others.
Overall, this article will get you acquainted with some types of medications dental professionals use in caring for their patient's teeth. If you want to know them,
then read them on.
1. Conscious Sedation Drugs
Many individuals experience anxiety when visiting a dentist. As such, a dentist may apply conscious sedation to ease such feelings. Conscious sedation is part
of sedation dentistry in which a dentist alleviates dental anxiety by using sedative medications.
The National Institutes of Health stated that you'll still be awake through conscious sedation. However, you'll become more unmindful of the dental procedure.
Also, you may forget what occurred afterward. Note that conscious sedation differs from general anesthesia, which assists in making you wholly unconscious, and
dentists generally employ this for lengthy dental procedures.
Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up
recruitment in studies conducted by drugmakers.
With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively
match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and
access to an extensive foundation of pharmacy and patient-authorised clinical data.
The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants,
the company will be able to reduce the time it takes to match eligible patients to clinical trials.
"Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive
solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer,
Walgreens.
The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone
receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour.
The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back
following surgery compared with people having hormone therapy alone.
Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib
received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition
to support patient access to clinically and cost effective treatments as early as possible.
"Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement
in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood
of developing incurable advanced disease."
The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high
risk of severe Covid-19 on Thursday (16 February).
The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on
4 April 2023.
It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19,
which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US.
NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of
the variants circulating in the UK now and in the near future.
It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made
available more quickly to patients if they show promise against new variants and are found to be cost-effective.
The National Pharmacy Association (NPA) has been in dialogue with the senior management of NHS Property Services to bring down the rent for community
pharmacies based in NHS health centres.
Association said: "Community pharmacies based in NHS health centres are struggling to make ends meet due to expensive rental rates."
It is calling for pharmacies to have the ability to renegotiate rental rates part way through a contract.
Gareth Jones, Director of Corporate Affairs at the NPA, said landlords need to take into account that pharmacy spending power is shrinking and the previous formula
used to set rental rates is no longer fit for purpose.
"It no longer makes sense to calculate based on historical assumptions about how many prescriptions the co-located GP will generate for the pharmacy," he said.
Chair of the health and social care committee Steve Brine and England's chief pharmacist David Webb are among a raft of speakers who will be addressing
delegates at the 13th Annual Sigma Community Pharmacy Conference to be held in Punta Cana, Dominican Republic from Sunday (March 5).
Day I of the conference will also feature a Q&A session with PSNC CEO Janet Morrison and her lead negotiator Mike Dent, which will be presented as a live webinar
via YouTube for those unable to attend in person.
Sigma Pharmaceuticals has invited all interested community pharmacists and stakeholders in the UK to join the 90 minutes session by clicking this link.
Those joining the session will not only be able to listen to the Q&A session - which will run between 6.30PM and 8.00PM in UK on Sunday - but also ask questions to
the PSNC executives via a live YouTube chat.
Sigma says the operating landscape for community pharmacy has altered dramatically since it last held its 'away conference' in the Philippines in February 2020. The
role of the independents - post pandemic - has rapidly evolved and has now been recognised by the health secretary as playing a significant part in the health of
the nation.
The National Pharmacy Association (NPA) and Royal Pharmaceutical Society (RPS) has been appointed as a core participant in the Covid-19 public inquiry.
The independent public inquiry has been set up to examine the UK's response to and the impact of the Covid-19 pandemic and learn lessons to shape preparations for
future pandemics. It is chaired by Baroness Heather Hallett, a former Court of Appeal judge.
The NPA and RPS will be part of Module 3, which covers the impact of Covid-19 on healthcare systems across the United Kingdom. The preliminary hearing for that
module takes place on Tuesday 28 February.
This will give the association an opportunity to make opening and closing statements, consider evidence provided to the Inquiry and propose questions to be asked by
the Inquiry of witnesses.
NPA chief executive, Mark Lyonette, said: "This is an historic opportunity to place on record the achievements of community pharmacy during the pandemic and to ensure
that the inquiry's recommendations are based in the practical realities faced by health workers such as our members.
The National Pharmacy Association (NPA) survey revealed that 93 per cent of respondents experienced 'at least one month' of negative cash flow across their
pharmacy business in 2022.
Nine out of 10 pharmacy owners responding to NPA survey said they made a net loss dispensing medicines for the NHS during 2022, for at least one month of the year.
According to the poll, 48 per cent of them lost money on this core NHS service for six months or more. 45 per cent said their overall outgoings had exceeded overall
income in at least six months of the year.
NPA Chair Andrew Lane said: "This survey shows the bleak financial reality facing many independent pharmacies after years of underfunding. Dispensing at a loss and
negative cashflow is clearly unsustainable."
"This funding crisis must be addressed urgently or pharmacies will fall into a spiral of declining services and ultimately widespread closures, he added. "Tragically,
the story is playing out very much in line with independent research commissioned by the NPA last year, which warned of a nationwide financial emergency in our
sector."
While Northern Irish business groups has welcomed the certainty a new EU-UK deal on post-Brexit trade rules for the region provided, the pharmaceutical
industry too has expressed cautious optimism.
In his speech on the Windsor Framework on Monday (February 28) Prime Minister Rishi Sunak said the agreement "delivers a landmark settlement on medicines".
"From now on, drugs approved for use by the UK's medicines regulator will be automatically available in every pharmacy and hospital in Northern Ireland," he
announced.
The National Pharmacy Association's Northern Ireland manager Anne McAlister expressed a sense of cautious optimism.
She said: "While the devil may yet be in the detail, the Windsor Framework would appear to be good news for pharmacies in Northern Ireland. It seems to address
the main concerns we have expressed about medicines supplies to NI, but we want to examine the small print to ensure the new arrangements meet the needs of our
members and the patients they serve.
The National Pharmacy Association (NPA) highlighted the role played by community pharmacies during pandemic to provide urgent care and vital support to people
with long-term medical conditions at its opening remark in the Covid-19 public inquiry held on Tuesday (28 February).
NPA is the core participant in the Covid-19 public inquiry. lawyer Brian Stanton made an opening statement on the NPA's behalf which focused on three areas- health
inequalities and the needs of vulnerable patients; the impact of medicine shortages and medicine price increases and the challenge that community pharmacy faced in
responding to the pandemic and maintaining patient services following long-term under investment.
Stanton said: "The UK's community pharmacies were on the frontline of efforts to limit the impact of coronavirus and to keep people well, and as well as handling a
massive increase in demand for healthcare advice and medicines, they also continued to provide urgent care and vital support to people with long-term medical
conditions.
"However, there are now very many at risk of closure during to underfunding and when the Inquiry comes to consider its recommendations the NPA would encourage
you [the presiding judge] to think about how resilience can be built into future plans."
The statement included a compelling account of the commitment typical of so many pharmacies during the pandemic - from husband and wife Pete and Sukhi Johal, both
NPA members and pharmacists, who co-own Calow Pharmacy in Chesterfield.
The National Pharmacy Association (NPA) has called on the NHS England to uplift funding for pharmacy contractors to enable them to cover higher staffing costs
along with a range of other cost-inflating factors.
This follows latest data released by the recruitment platform Locate a Locum, which showed a huge increase in locum rates for pharmacists in 2021 and predicted the
trend to continue.
The report noted a 71 per cent surge in the cost of employing locum pharmacists in England, from the 2020 average to the second half of 2021.
NPA chief executive Mark Lyonette said: "There is a heavy reliance on locums in community pharmacy to maintain continuity of services with the average pharmacy
operating 50 hours per week. Consequently, increases in locum rates have a big effect on the cost base.
"Pharmacies face a range of general cost pressures beyond locum rates, including much higher energy costs. We hear a lot about the cost of living crisis; our
members are facing a cost of doing business crisis and it's every bit as real.
"The underlying underfunding, significant general inflationary pressures and specific cost increases relating to the locum workforce together make a powerful and
urgent case for new funding."
In response to a Scottish government consultation, the National Pharmacy Association (NPA) has called for continued investment to develop community pharmacy teams and create additional capacity in existing services.
The consultation examines different ways patients access healthcare services in Scotland and focuses on sources of healthcare other than GPs that exist in the community.
The inquiry was discussed with NPA policy leads across the UK, NPA Scottish members and other Scottish pharmacy stakeholder organisations.
The NPA stated that services delivered during the pandemic has proven the importance of Scotland's 1,258 community pharmacies, and believes additional capacity for existing pharmacy services, and expansion of pharmacy Public Health Services is possible with continued investment from the government.
The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition.
NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.
The National Institute for Health and Care Excellence (NICE)'s independent committee has called for more research to ensure liposuction for treatment of chronic lipoedema is safe and effective enough for use on the NHS.
Lipoedema is more prevalent in women and very rarely affects men. It is characterised by an abnormal, usually symmetrical, accumulation of fat in the legs, hips, buttocks, and occasionally arms. It is a separate condition to obesity and lymphoedema.
The cause of lipoedema is unknown, but hormonal changes, weight gain and genetics are thought to be involved. The size and shape of legs, and the resultant mobility issues and pain, can have a profoundly negative effect on quality of life, and physical and mental health.
The interventional procedures advisory committee reviewed evidence from several sources, including eight before-and-after studies. The committee was informed that
several different liposuction techniques are used and that they may have different safety and efficacy profiles.
Type 1 diabetes patients can monitor their glucose with the newly introduced flash glucose monitors by the NHS.
The wearable gadgets with the size of a £2 coin, have a sensor that easily sits on the arm, allowing patients to check their glucose levels with a one-second scan.
Eligible patients are currently able to access the monitors on prescription from their local GP or diabetes team, helping them to better manage their blood sugar levels.
Everyone living with type 1 diabetes will be eligible for lifechanging flash glucose monitors on the NHS. The NHS Long Term Plan has already helped almost three in
five people with Type 1 diabetes to access the monitors that allow people to check their glucose levels more easily and regularly.
The change, confirmed today by the National Institute for Health and Care Excellence (NICE), means that everyone in England with the condition will be able to benefit from the convenient technology.
The cardiac surgery cost in India is less expensive than a majority of nations within the world. That is more often than not due to numerous best centers for cardiac surgeries and the fact that valves used for the surgical treatment are commonly synthetic and are available within the limitation of the country.
The cardiac surgery cost in India is less expensive than a majority of nations within the world.India stands for offering cost cardiac surgery India with the high success rates from over 150,000 several cardiac techniques done every year.
The national pharmacy bodies has created 'Save Our Pharmacies' campaign website to give new focus to calls for fair pharmacy funding in England.
The newly launched site contains key messages for public, politicians and stakeholders, and hosts campaign resources to be used by pharmacy teams.
The pharmacy bodies encourage members of the public and pharmacy teams to show their support for the campaign on social media, as well as signing the petition
and contacting their local MPs about fair funding.
A further resource in the form of a window poster is being printed and will shortly be mailed out to all community pharmacies in England.
It is the latest output of a joint programme of work being coordinated by PSNC, CCA, AIM and the NPA.
Community pharmacies in Cornwall have delivered more than 8000 face-to-face consultations over last 12 months.
Walk In Consultation Service (WICS) began 12 months ago when pharmacies in Cornwall started offering face-to-face consultations for a wide range of minor ailments,
and NHS treatment as required - the first service of its kind in England.
Cornwall & Isles of Scilly Scilly Local Pharmaceutical Committee (LPC) Chief Officer Nick Kaye joined Operations Manager Drew Creek in Parliament recently by invite
of Steve Double MP, St Austell and Newquay to meet with Minister for Health Neil O'Brien MP to present the service to them and Senior Civil Servants from DHSC and
NHSE with a view to rolling this service out nationally.
The data from these consultations show that over 6000 GP appointments were averted as a result of the service being available. After each consultation a record was
sent to the patient's GP for information.